Mass Tort Settlement Tracker

$10.5 billion to $12.5 billion paid over 13 years to public water systems for PFAS contamination, per the official settlement FAQ. Final approval entered by Judge Gergel (fairness hearing February 2, 2024). Compensates water utilities, not individuals.

The litigation has involved settlement activity and individual case resolution, but no single court-approved global public settlement amount resolves all claims. Individual outcomes depend on product, injury, revision surgery, and proof.

No global public settlement has been announced for the federal MDL. Case value and eligibility depend on device proof, injury proof, causation, and individual facts.

The DOJ/Navy Elective Option offers tiered payments of roughly $100,000 to $450,000 depending on diagnosis and exposure duration, plus $100,000 for qualifying wrongful-death claims (up to $550,000 combined). Per DOJ figures dated May 15, 2026, more than $876 million in settlements had been offered and approximately $665 million paid. Elective Option payments are not reduced by VA benefit offsets; recoveries outside the program may be subject to the CLJA's offset provisions.

No settlement program exists. The Rule 702 hearing listed for September 18, 2026, the pending preemption ruling, and the first Pilot trial set for December 7, 2026 are the events most likely to shape any settlement posture.

No global public settlement has been announced for the federal MDL. Individual outcomes, if any, depend on facts, proof, and court rulings.

J&J's three 'Texas Two-Step' bankruptcy attempts to cap talc liability were all rejected by the courts. Most recently, Red River Talc LLC's prepackaged Chapter 11 — built around a proposed roughly $9 billion plan — was denied by U.S. Bankruptcy Judge Christopher Lopez in the Southern District of Texas on March 31, 2025. No global settlement is in place; ovarian-cancer claims are coordinated in MDL-2738 and individual cases are being tried in state courts.

No global or individual settlement program has been announced. The Rule 702 and summary judgment rulings expected after the September 2026 hearings are the litigation's next major value-shaping events. Industry estimates of potential exposure are not promises: no outcome is guaranteed and defendants continue to dispute the claims.

No global settlement is in place. The first bellwether trial ended in a defense verdict for Teva in February 2026, and the court then weighed revising the bellwether plan. Additional bellwether trials are scheduled in 2026, and individual eligibility and any future settlement posture remain fact-specific. No amount is guaranteed for any individual claim.

Executed September 3, 2025, according to Case Management Order No. 24. The public court orders do not provide settlement tiers, a payout grid, or an average per-claim value. The court selected certain opt-out cases for limited discovery in June 2026.

The proposed settlement would provide up to $7.25 billion over roughly 21 years. It received preliminary approval on March 4, 2026. The official settlement website says the fairness hearing was rescheduled to August 19, 2026, and final approval has not been granted.

There is no global or program settlement in MDL-3047 or the California JCCP. Some defendants have reached confidential settlements in individual bellwether cases: in the first Los Angeles JCCP personal-injury bellwether, a jury awarded $6 million in March 2026 against Meta and YouTube, while Snap and TikTok had settled that case before trial; ahead of the second personal-injury bellwether set for July 27, 2026, YouTube reached a confidential settlement in June 2026. No amount is guaranteed for any individual claim.

No settlement program exists. The litigation is in bellwether selection; core-discovery and trial-pool steps run through 2027 under the court's bellwether protocol before any trial.